Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

Abstract Background This analysis estimated the number needed to treat with enzalutamide versus bicalutamide to achieve one additional patient with chemotherapy-naïve metastatic castration-resistant prostate cancer who would obtain clinical benefit regarding progression-free survival, radiographic p...

Full description

Bibliographic Details
Main Authors: Neil M. Schultz, Neal D. Shore, Simon Chowdhury, Laurence H. Klotz, Raoul S. Concepcion, David F. Penson, Lawrence I. Karsh, Hongbo Yang, Bruce A. Brown, Arie Barlev, Scott C. Flanders
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Urology
Subjects:
Enzalutamide
Bicalutamide
Metastatic castration-resistant prostate cancer
Number needed to treat
Online Access:http://link.springer.com/article/10.1186/s12894-018-0387-7

Internet

http://link.springer.com/article/10.1186/s12894-018-0387-7

Similar Items